Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Italy / epidemiology
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Retrospective Studies
  • Salvage Therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • elotuzumab
  • Dexamethasone
  • Lenalidomide